Analytical Data
-
Gene name
MAGED1
- Application
-
Alternative Names
MAGED1;NRAGE;Melanoma-associated antigen D1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9Y5V3
-
Expression Region
504-760aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MGSLRPSPNS RASQNPGAAQ PRDVALLQER ANKLVKYLML KDYTKVPIKR SEMLRDIIRE YTDVYPEIIE RACFVLEKKF GIQLKEIDKE EHLYILISTP ESLAGILGTT KDTPKLGLLL VILGVIFMNG NRASEAVLWE ALRKMGLRPG VRHPLLGDLR KLLTYEFVKQ KYLDYRRVPN SNPPEYEFLW GLRSYHETSK MKVLRFIAEV QKRDPRDWTA QFMEAADEAL DALDAAAAEA EARAEARTRM GIGDEAVSGP
-
Molecular Weight
32 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MAGED1 (Melanoma Associated Gene D1) is a member of the MAGED gene family, which has been implicated in various physiological and pathological processes, including tumorigenesis. Initially identified as a gene expressed in melanoma cells, MAGED1 has garnered interest due to its potential role in cancer biology, specifically its involvement in regulating cell proliferation and apoptosis. Recent studies suggest that MAGED1 may also contribute to the immune response and the modulation of tumor immune evasion. Given its expression in various tumors and its potential as a cancer biomarker, understanding the functional properties of MAGED1 through recombinant protein studies is crucial. This research focuses on characterizing the biochemical and biophysical properties of MAGED1 to elucidate its role in cancer and explore its potential as a therapeutic target. By producing recombinant MAGED1, researchers aim to investigate its interactions with other cellular proteins, assess its effects on cellular pathways, and evaluate its implications for diagnostic and therapeutic strategies in cancer treatment. Ultimately, this foundational work is vital for advancing our understanding of MAGED1's contributions to cancer and harnessing its potential in clinical applications.











